NEW YORK (Reuters) - Pfizer Inc's PFE.N Chief Executive Albert Bourla said on Tuesday that once it knows whether the vaccine candidate it is developing with Germany's BioNTech SE 22UAy.F works, it could be a week before it lets the public know, making it unlikely it will release data before the Nov. 3 presidential election.
“In case of a conclusive readout, positive or negative, we will inform the public as soon as we complete the necessary administrative work, which we estimate to be completed within one week from the time we know,” Bourla said, speaking on a company conference call. Pfizer said earlier on Tuesday it was not yet ready to release data from the late-stage trial of the COVID-19 vaccine.
Reporting by Michael Erman; Editing by Chizu Nomiyama
Our Standards: The Thomson Reuters Trust Principles.